Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2019 - 2026)
Zentalis Pharmaceuticals' quarterly Share-based Compensation came in at $3.2 million in Q1 2026, down 50.71% year-on-year from $6.5 million in Q1 2025, and up 2.4% quarter-over-quarter from $3.1 million in Q4 2025.
Zentalis Pharmaceuticals has reported Share-based Compensation for 8 years, with the latest figure at $3.2 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 50.71% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $17.4 million (down 71.38% YoY), and the FY2025 full-year result was $20.7 million, down 69.2% from the prior year.
- Share-based Compensation for Q1 2026 stood at $3.2 million, up from $3.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $31.4 million in Q4 2024, with the low at $3.1 million in Q4 2025.
- Average Share-based Compensation over 5 years is $11.3 million, with a median of $10.4 million recorded in 2024.
- Year-over-year, Share-based Compensation surged 125.96% in 2024 and tumbled 90.05% in 2025.
- Tracing ZNTL's Share-based Compensation over 5 years: stood at $9.6 million in 2022, then surged by 44.4% to $13.9 million in 2023, then surged by 125.96% to $31.4 million in 2024, then plunged by 90.05% to $3.1 million in 2025, then increased by 2.4% to $3.2 million in 2026.
- The last three Share-based Compensation figures came in at $3.2 million (Q1 2026), $3.1 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | 3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.20 Mn |
| Mar 31, 2026 | 3.20 Mn |
| Dec 31, 2025 | 3.12 Mn |
| Dec 31, 2025 | 3.12 Mn |
| Sep 30, 2025 | 4.83 Mn |
| Sep 30, 2025 | 4.83 Mn |
| Jun 30, 2025 | 6.29 Mn |
| Jun 30, 2025 | 6.29 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 31.36 Mn |
| Dec 31, 2024 | 31.36 Mn |
| Sep 30, 2024 | 10.36 Mn |
| Sep 30, 2024 | 10.36 Mn |
| Jun 30, 2024 | 12.71 Mn |
| Jun 30, 2024 | 12.71 Mn |
| Mar 31, 2024 | 12.83 Mn |
| Mar 31, 2024 | 12.83 Mn |
| Dec 31, 2023 | 13.88 Mn |
| Dec 31, 2023 | 13.88 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 13.34 Mn |
| Jun 30, 2023 | 13.34 Mn |
| Mar 31, 2023 | 13.73 Mn |
| Mar 31, 2023 | 13.73 Mn |
| Dec 31, 2022 | 9.61 Mn |
| Dec 31, 2022 | 9.61 Mn |
| Sep 30, 2022 | 10.32 Mn |
| Sep 30, 2022 | 10.32 Mn |
| Jun 30, 2022 | 16.76 Mn |
| Jun 30, 2022 | 16.76 Mn |
| Mar 31, 2022 | 10.15 Mn |
| Mar 31, 2022 | 10.15 Mn |
| Dec 31, 2021 | 8.47 Mn |
| Dec 31, 2021 | 8.47 Mn |
| Sep 30, 2021 | 7.66 Mn |
| Sep 30, 2021 | 7.66 Mn |
| Jun 30, 2021 | 9.92 Mn |
| Jun 30, 2021 | 9.92 Mn |
| Mar 31, 2021 | 9.69 Mn |
| Mar 31, 2021 | 9.69 Mn |
| Dec 31, 2020 | 7.89 Mn |
| Dec 31, 2020 | 7.89 Mn |
| Sep 30, 2020 | 7.25 Mn |
| Sep 30, 2020 | 7.25 Mn |
| Jun 30, 2020 | 7.68 Mn |
| Jun 30, 2020 | 7.68 Mn |
| Mar 31, 2020 | 329,000.00 |
| Mar 31, 2020 | 329,000.00 |
| Dec 31, 2019 | 212,000.00 |
| Dec 31, 2019 | 212,000.00 |
| Sep 30, 2019 | 155,000.00 |
| Sep 30, 2019 | 155,000.00 |
| Jun 30, 2019 | 121,000.00 |
| Jun 30, 2019 | 121,000.00 |
| Mar 31, 2019 | 129,000.00 |
| Mar 31, 2019 | 129,000.00 |